Development and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia
Thomas Briot,1,2 Emilie Roger,1 Nolwenn Lautram,1 Alexis Verger,1 Anne Clavreul,3,4 Frederic Lagarce1,2 1Micro & Nanomédecines Translationelles – MINT, UNIV Angers, INSERM 1066, CNRS 6021, Université Bretagne Loire, MINT IBS-CHU, 2Pharmacy Department, Univers...
Guardado en:
Autores principales: | Briot T, Roger E, Lautram N, Verger A, Clavreul A, Lagarce F |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/10cc6ce309724deab6b1db65a8fc0bd4 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Use of Azacitidine or Decitabine for the Up-Front Setting in Acute Myeloid Leukaemia: A Systematic Review and Meta-Analysis
por: Miriam Saiz-Rodríguez, et al.
Publicado: (2021) -
Conventional Cytogenetic and Molecular Analysis in Acute Myeloid Leukemia (AML) and Their Association with Overall Survival
por: Shakeri S., et al.
Publicado: (2021) -
IRF2-INPP4B-mediated autophagy suppresses apoptosis in acute myeloid leukemia cells
por: Zhang,Feng, et al.
Publicado: (2019) -
TRIM25 contributes to the malignancy of acute myeloid leukemia and is negatively regulated by microRNA-137
por: Wang Sheng, et al.
Publicado: (2020) -
Circular RNAs in acute myeloid leukemia
por: Vijendra Singh, et al.
Publicado: (2021)